Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 3
2017 2
2023 2
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Locally advanced basal cell carcinoma associated with distinct gut microbiome signature.
Moreno-Arrones OM, Béa-Ardebol S, Galiano-Mejías S, Turrión-Merino L, de Perosanz-Lobo D, Perez-Brocal V, Moya A, Rios-Buceta L. Moreno-Arrones OM, et al. Among authors: galiano mejias s. J Dtsch Dermatol Ges. 2024 Oct 15. doi: 10.1111/ddg.15588. Online ahead of print. J Dtsch Dermatol Ges. 2024. PMID: 39410728 No abstract available.
Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study.
Moreno-Arrones OM, Béa-Ardebol S, Mayo-Martinez F, Pérez-Pastor G, Torres-Navarro I, Bonfill-Ortí M, Deza G, Ruiz-Salas V, Masferrer E, Feal C, Turrión-Merino L, Toll A, Yébenes M, Galiano-Mejías S, Jaka A, Ferrandiz-Pulido C, Florez A, Hernández-Hernández N, Fernández-de-Misa R, Rios-Buceta L, Sanmartin O. Moreno-Arrones OM, et al. Among authors: galiano mejias s. Actas Dermosifiliogr. 2023 Jul-Aug;114(7):T565-T571. doi: 10.1016/j.ad.2023.06.011. Epub 2023 Jun 9. Actas Dermosifiliogr. 2023. PMID: 37302483 Free article. English, Spanish.
Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study.
Moreno-Arrones OM, Béa-Ardebol S, Mayo-Martinez F, Pérez-Pastor G, Torres-Navarro I, Bonfill-Ortí M, Deza G, Ruiz-Salas V, Masferrer E, Feal C, Turrión-Merino L, Toll A, Yébenes M, Galiano-Mejías S, Jaka A, Ferrandiz-Pulido C, Florez A, Hernández-Hernández N, Fernández-de-Misa R, Rios-Buceta L, Sanmartin O. Moreno-Arrones OM, et al. Among authors: galiano mejias s. Actas Dermosifiliogr. 2023 Jul-Aug;114(7):565-571. doi: 10.1016/j.ad.2023.04.022. Epub 2023 Apr 23. Actas Dermosifiliogr. 2023. PMID: 37088285 Free article. English, Spanish.
Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry.
Galiano Mejías S, Carretero G, Ferrandiz C, Vanaclocha F, Daudén E, Gómez-García FJ, Herrera-Ceballos E, Belinchón-Romero I, Sánchez-Carazo JL, López-Estebaranz JL, Alsina M, Ferrán M, Torrado R, Carrascosa JM, Rivera R, Llamas-Velasco M, Jiménez-Puya R, Mendiola MV, Ruiz-Genao D, Descalzo MA, de la Cueva Dobao P; del grupo Biobadaderm. Galiano Mejías S, et al. Actas Dermosifiliogr. 2017 Jan-Feb;108(1):52-58. doi: 10.1016/j.ad.2016.08.003. Epub 2016 Sep 20. Actas Dermosifiliogr. 2017. PMID: 27658689 Free article. English, Spanish.
Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry.
Dávila-Seijo P, Dauden E, Descalzo MA, Carretero G, Carrascosa JM, Vanaclocha F, Gómez-García FJ, De la Cueva-Dobao P, Herrera-Ceballos E, Belinchón I, López-Estebaranz JL, Alsina M, Sánchez-Carazo JL, Ferrán M, Torrado R, Ferrandiz C, Rivera R, Llamas M, Jiménez-Puya R, García-Doval I; BIOBADADERM Study Group. Dávila-Seijo P, et al. J Invest Dermatol. 2017 Feb;137(2):313-321. doi: 10.1016/j.jid.2016.08.034. Epub 2016 Sep 25. J Invest Dermatol. 2017. PMID: 27677836 Free article.
Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort.
García-Doval I, Pérez-Zafrilla B, Ferrandiz C, Carretero G, Daudén E, de la Cueva P, Gómez-García FJ, Herrera-Ceballos E, Belinchón-Romero I, Sánchez-Carazo JL, López-Estebaranz JL, Alsina M, Ferrán M, Torrado R, Carrascosa JM, Rivera R, Vanaclocha F; BIOBADADERM Study Group. García-Doval I, et al. J Dermatolog Treat. 2016;27(3):203-9. doi: 10.3109/09546634.2015.1088130. Epub 2015 Sep 25. J Dermatolog Treat. 2016. PMID: 26367799 Free article.
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
Carretero G, Ferrandiz C, Dauden E, Vanaclocha Sebastián F, Gómez-García FJ, Herrera-Ceballos E, De la Cueva-Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina-Gibert M, López-Estebaranz JL, Ferrán M, Torrado R, Carrascosa JM, Carazo C, Rivera R, Jiménez-Puya R, García-Doval I; BIOBADADERM Study Group. Carretero G, et al. J Eur Acad Dermatol Venereol. 2015 Jan;29(1):156-63. doi: 10.1111/jdv.12492. Epub 2014 Mar 31. J Eur Acad Dermatol Venereol. 2015. PMID: 24684267